Amino Acid Auxotrophy Cured Prokaryotic Strain for Recombinant Polypeptide Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for recombinant polypeptide production using mutant prokaryotic strains in chemically defined minimal growth media are hindered by auxotrophies, requiring supplementation of expensive amino acids, which increases cultivation costs and reduces product titer compared to wild-type strains.
Innovation Solution
Curing auxotrophies in prokaryotic strains allows them to grow in chemically defined minimal growth media without additional amino acid supplementation, maintaining or increasing product titer and reducing costs by optimizing metabolic pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mutant prokaryotic strains are used for recombinant polypeptide production, then product titer can be increased, but auxotrophies require supplementation of expensive amino acids increasing cultivation costs
Solution Approach 1:
The patent removes the auxotrophic defect from the mutant strain by curing the amino acid synthesis pathway deficiency, extracting the harmful metabolic limitation while preserving the high product titer capability of the mutant strain
Solution Approach 2:
The patent changes the metabolic parameter of the strain by restoring amino acid synthesis capability through genetic correction, transforming the strain from auxotrophic (requiring amino acid supplementation) to prototrophic (capable of synthesizing amino acids autonomously)
2Productivity
If auxotrophic mutant strains are used, then product titer may be improved, but the complexity of medium requirements increases due to amino acid supplementation needs
Solution Approach 1:
The patent eliminates the need for complex medium supplementation by removing the auxotrophic requirement, simplifying the cultivation medium from chemically defined medium requiring amino acid additions to simple minimal medium
3Speed
If wild-type strains are used for cultivation in chemically defined minimal growth medium, then good growth characteristics are achieved, but product titer is inferior compared to mutant strains
Solution Approach 1:
The patent merges the advantageous traits of both wild-type and mutant strains: the good growth characteristics of wild-type strains and the high product titer of mutant strains, creating a hybrid strain that exhibits both properties simultaneously
Solution Approach 2:
The patent modifies the genetic parameters of the wild-type strain by introducing the high-productivity traits from mutant strains while correcting the auxotrophic defects, thereby changing both growth and production parameters to optimal levels
Data Source
AI summary
Herein is reported a method for producing a polypeptide in a prokaryotic cell, comprising the step of cultivating a prokaryotic cell comprising one or more nucleic acids encoding the polypeptide in a chemically defined minimal growth medium and recovering the polypeptide from the prokaryotic cell or the periplasm of the prokaryotic cell or from the medium, wherein the prokaryotic cell is an amino acid auxotrophy cured prokaryotic cell, wherein growth of the amino acid auxotrophy cured prokaryotic cell compared to the non-cured prokaryotic cell under the same cultivation conditions and in the same growth medium requires the supplementation of fewer amino acids to the growth medium, and wherein the chemically defined minimal growth medium is free of the amino acid corresponding to the auxotrophy that has been cured in the auxotrophy cured prokaryotic cell.